TABLE 2

Patient characteristics

Case numberTime of onset of ICIICI agent (clinical trial or RC)Events between onset of ICI and IPTime of IP onsetTime of IP onset after beginning of ICI monthsIP severity grade according to CTCAE 4.0SymptomsDiagnostic methodICI interruption or discontinuationSteroid treatmentIP outcome
1April 2015P (RC)Concurrent Pseudomonas aeruginosa pneumoniaJune 2017264Respiratory failureBALDiscontinued June 2017YesDeath after initial clinical and radiological improvement
2Aug 2016N (clinical trial)Cryotherapy of the chest wall metastasisOct 2017133DyspnoeaResponse to therapyDiscontinued Sept 2017YesClinical and radiological improvement
3July 2016I+N then N (RC)NoApril 201791NoneHistology (surgical excision)NoNoClinical and radiological improvement
4Dec 2016I+N then N (RC)NoMarch 201733Dyspnoea, coughBALDiscontinued March 2017YesClinical and radiological improvement
5July 2016I+N then N (RC)NoDec 201651NoneBALDiscontinued Dec 2016NoClinical and radiological improvement
6Nov 2016N (RC)NoFeb 201723DyspnoeaResponse to therapyDiscontinued Feb 2017YesClinical and radiological improvement
7April 2016D+T (clinical trial)NoJune 201623Dyspnoea, coughBALDiscontinued June 2016YesClinical and radiological improvement
8June 2016N (RC)NoJuly 2017131NoneBALDiscontinued June 2017YesClinical and radiological improvement
9May 2015I (clinical trial)NoSept 201541NoneBAL and histologyDiscontinued June 2017YesClinical and radiological improvement
10Oct 2015N (RC)NoJuly 201684DyspnoeaBALDiscontinued July 2016YesClinical and radiological improvement
11Aug 2016I+N (RC)NoOct 201621NoneHistologyDiscontinued Oct 2016YesClinical and radiological improvement
12March 2017P (clinical trial)NoSept 201761Dyspnoea, coughBALNoNoSlowed progression
13Sept 2016N (RC)Unproven superimposed infection of the RULFeb 201753DyspnoeaBALDiscontinued Feb 2017YesClinical and radiological improvement
14Sept 2010I (RC)NoOct 201013CoughBALDiscontinued Oct 2010YesClinical and radiological improvement
15Aug 2016N (RC)RTFeb 2018173DyspnoeaBALDiscontinued Jan 2018YesClinical and radiological improvement

ICI: immune checkpoint inhibitors; RC: routine care; IP: immune-related pneumonitis; CTCAE: Common Terminology Criteria for Adverse Events; P: pembrolizumab; N: nivolumab; I: ipilimumab; D: durvalumab; T: tremelimumab; RUL: right upper lobe; RT: radiotherapy; BAL: bronchoalveolar lavage.